Therefore, GIP receptor (GIPR) agonism has not been pursued in the treatment of type 2 diabetes, but novel GLP-1/GIP receptor agonists may soon redefine the pharmacological role of GIP. This evidence concerns the gene GIPR and type 2 diabetes mellitus.